Sigma Planning Corp Reduces Holdings in uniQure (NASDAQ:QURE)

Sigma Planning Corp lessened its holdings in uniQure (NASDAQ:QURE) by 3.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 46,745 shares of the biotechnology company’s stock after selling 1,500 shares during the period. Sigma Planning Corp’s holdings in uniQure were worth $826,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of QURE. RTW Investments LP acquired a new position in shares of uniQure during the 3rd quarter worth approximately $49,000. China Universal Asset Management Co. Ltd. increased its position in uniQure by 57.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock worth $50,000 after buying an additional 3,663 shares in the last quarter. Atria Investments Inc acquired a new position in shares of uniQure in the third quarter worth $53,000. Quarry LP purchased a new stake in shares of uniQure in the third quarter valued at $58,000. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of uniQure during the third quarter valued at $69,000. 78.83% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the stock. HC Wainwright boosted their target price on shares of uniQure from $25.00 to $70.00 and gave the company a “buy” rating in a research note on Monday, January 27th. The Goldman Sachs Group lifted their price target on shares of uniQure from $9.00 to $20.00 and gave the stock a “neutral” rating in a report on Thursday, December 12th. Stifel Nicolaus upped their price objective on shares of uniQure from $12.00 to $32.00 and gave the company a “buy” rating in a research note on Monday, December 16th. Leerink Partners lifted their target price on shares of uniQure from $26.00 to $44.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 11th. Finally, Cantor Fitzgerald boosted their price target on uniQure from $28.00 to $58.00 and gave the company an “overweight” rating in a report on Tuesday, December 10th. One analyst has rated the stock with a sell rating, two have issued a hold rating, six have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $40.00.

uniQure Stock Performance

NASDAQ:QURE opened at $10.99 on Wednesday. The company has a market cap of $535.69 million, a P/E ratio of -2.22 and a beta of 0.39. The firm’s 50 day moving average is $15.38 and its two-hundred day moving average is $9.69. uniQure has a fifty-two week low of $3.73 and a fifty-two week high of $19.18. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92.

Insider Transactions at uniQure

In related news, CEO Matthew C. Kapusta sold 3,418 shares of uniQure stock in a transaction on Monday, December 9th. The stock was sold at an average price of $7.63, for a total value of $26,079.34. Following the transaction, the chief executive officer now owns 597,915 shares in the company, valued at approximately $4,562,091.45. This trade represents a 0.57 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 4.74% of the company’s stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.